Search academic texts

Information × Registration Number 0218U001410, 0116U003575 , R & D reports Title Role of molecular genetic of somatic cells, pharmacological and chemical characteristics of ABO antigens and medicinal drugs in selection of individualized therapy programs in patients with chronic lymphoproliferative neoplasms popup.stage_title Head Minchenko Zhanna; Liubarets Tatiana, Registration Date 08-02-2018 Organization State institution "National research centеr for radiation medicine of the National academy of medical sciences of Ukraine " popup.description2 The object of the study is clinical and hematological, immunogenetic, molecular-cytogenetic characteristics of chronic lymphoproliferative neoplasms (ChLN), including chronic lymphocytic leukemia (CLL) and рlasma cell myeloma (PCM). Objective is to determine the most informative prognostic criteria for the effectiveness of individualized therapy based on clinical and hematological parameters, immunogenetic and cytokine profile, molecular cytogenetic and molecular genetic characteristics of substrate cells in patients with chronic lymphoproliferative neoplasms. Methods of investigation - clinical, hematological, molecular cytogenetic, immunogenetic, immunological, statistical. The database included 247 cases of ChLN: 136 cases of CLL, and 111 cases of PCM. In patients with PCM were revealed a probable increase in the frequency of the TGF-beta codon 10 T / T genotype (0.591, p <0.05) as a probable immunogenic predisposition factor of disease; significant increase in the frequency of IB allele in patients with chronic renal failure (ChRF); a significant increase in the remission period during standard PChT in patients with the presence of phenotype A; a significant decrease in the concentration of IL-6 and TNF-alpha as prognostic criteria for the course of the disease when complete / partial remission. No dependence of the CLL course on the presence of antigens on blood groups ABO and Rh was detected. The level of serum LDH is the most informative criterion for patients with CLL (F = 10.43; p <0.0001), for patients with PCM such criteria are urea level (F = 3.58; p = 0.05) and albumin (F = 4.00; p = 0.05). The use of antiCD20 - rituximab antibody significantly extends the OS and PFS of patients with CLL. There were established integral indices i. e. prognostic indexes (by definition ?2 Pyrson coefficient). In CLL patients they included the CLI stage according to the classifications Rai et al. (1975) (0-IV) and Binet et al. (1981) (A-C), the presence of B-symptoms, the Rh-factor of patients, gender, the presence / absence of irradiation, the inclusion / absence of rituximab in PChT schemes, the presence of other malignant tumors. In PCM patients they included a stage according to the Durie-Salmon (1975) (I-III) and ISS 1985 (I-III) classification, the paraprotein type, the presence of complications (ChRF), the status due to irradiation, the polymorphisms of the cytokines (IL-10, IFN-beta, TNF-alpha). Association of abnormalities of chromosome 13 (del13q34) with translocation t(4;14), and translocation t(14;16) with abnormalities of chromosome 16 was revealed in primary refractory disease or in PKM patients with minimal therapy effectiveness and disease complications (Ro Spirman=0,33; p<0,05). Product Description popup.authors Балан Валентина Володимирівна Бебешко Володимир Григорович Дмитренко Олена Олександрівна Мішаріна Жанна Анатоліївна Сілаєв Юрій Олегович Товстоган Анжела Олександрівна Хоменко Віктор Іванович Шляхтиченко Тетяна Юріївна popup.nrat_date 2020-04-02 Close